Showing 2646 results
- Media Library /
- Media Library /
- Media Library /
- Media Release /If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric…
- Media Release /Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers…
- Pulse Update /
- Media Release /The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
- Featured News /
Novartis announced the company’s financial results for the first quarter of 2023.
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 265
- › Next page